title: Novel antibiotics: are we still in the pre-post-antibiotic era?
abstract: OBJECTIVE
  Therapeutic efficacy and safety in infections due to multidrug-resistant bacteria can be improved by the clinical development of new compounds and devising new derivatives of already useful antibiotics. Due to a striking global increase in multidrug-resistant Gram-positive but even more Gram-negative organisms, new antibiotics are urgently needed.
  
  
  METHODS
  This paper provides a review of novel antibiotic compounds which are already in clinical development, mainly in phase III clinical trials.
  
  
  CONCLUSIONS
  Each of these new trials increases the possibility of new antibiotics receiving approval.
authors.affiliation: Sektion Infektiologie, Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Pettenkoferstr. 8a, 80336, Munich, Germany, rika.draenert@med.uni-muenchen.de.
authors.forename: R
authors.initials: R
authors.lastname: Draenert
authors.forename: U
authors.initials: U
authors.lastname: Seybold
authors.forename: E
authors.initials: E
authors.lastname: Grützner
authors.forename: J R
authors.initials: JR
authors.lastname: Bogner
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001419:Bacteria / Q000187:drug effects; D001424:Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D024881:Drug Resistance, Bacterial; D006801:Humans
chemical_list: D000900:Anti-Bacterial Agents